Timing of first exposure to DES and characteristic dose of DES in relation to breast cancer among women ages ≥40 years
| . | Person-years of follow-up . | No. cases . | Age-adjusted IRR (95% CI) . | |||
|---|---|---|---|---|---|---|
| Unexposed | 13,058 | 17 | Reference | |||
| Weeks of gestation of first exposure | ||||||
| ≤8 wk | 7,731 | 12 | 1.48 (0.69-3.16) | |||
| 9-12 wk | 6,511 | 14 | 2.04 (0.99-4.23) | |||
| ≥13 wk | 8,272 | 19 | 2.01 (1.03-3.90) | |||
| Characteristic dose in cohort* | ||||||
| Low dose | 12,215 | 22 | 1.63 (0.86-3.11) | |||
| High dose | 16,160 | 36 | 2.17 (1.18-3.97) | |||
| Unknown | 973 | 2 | 1.75 (0.40-7.65) | |||
| . | Person-years of follow-up . | No. cases . | Age-adjusted IRR (95% CI) . | |||
|---|---|---|---|---|---|---|
| Unexposed | 13,058 | 17 | Reference | |||
| Weeks of gestation of first exposure | ||||||
| ≤8 wk | 7,731 | 12 | 1.48 (0.69-3.16) | |||
| 9-12 wk | 6,511 | 14 | 2.04 (0.99-4.23) | |||
| ≥13 wk | 8,272 | 19 | 2.01 (1.03-3.90) | |||
| Characteristic dose in cohort* | ||||||
| Low dose | 12,215 | 22 | 1.63 (0.86-3.11) | |||
| High dose | 16,160 | 36 | 2.17 (1.18-3.97) | |||
| Unknown | 973 | 2 | 1.75 (0.40-7.65) | |||
Low-dose cohort includes participants from hospitals in Texas, Minnesota, and Wisconsin. High-dose cohort includes participants from hospitals in Boston, Chicago, and California. Unknown includes participants from hospitals in New Hampshire and Maine.